Molecular characterization of colorectal neoplasia in translational research

Archives of Pathology and Laboratory Medicine

Volumn 125, Issue 1, 2001, Pages 91-98

  Grizzle, W E ^a   Manne, U ^a   Jhala, N C ^a   Weiss, H L ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOCHEMICAL MARKER; CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN; MUCIN; PROTEIN BCL 2; PROTEIN P53; TUMOR ANTIGEN;

ADENOCARCINOMA; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOID; COLORECTAL CARCINOMA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; GENE MUTATION; HUMAN; METASTASIS; PATHOGENESIS; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; GLYCOPROTEINS; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035138257     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Nuclear accumulation of p53 in colorectal adenocarcinoma: Prognostic importance differs with race and location of the tumor
2. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis
3. Phase II study of dual 131l-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer
4. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
5. Clinical evaluation of the new tumor marker TAG-72
6. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3
7. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer
8. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors
9. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes
10. Detection of microscopic melanoma metastases in sentinel lymph nodes
11. Tumor associated glucoprotein-72 is highly expressed in prostatic adenocarcinomas
12. Small cell neuroendocrine carcinoma of the colon and rectum: Clinical, histologic, and ultrastructural study and immunohistochemical comparison with cloacogenic carcinoma
13. Argentaffin and argyrophil reactions of human gastrointestinal carcinoids
14. Histiocytic lymphoma and malignant angioendotheliomatasis: One disease or two?
15. Reassessment of malignant "angioendotheliomatosis" - Evidence in favour of its reclassification as 'intravascular lymphomatosis.'
16. Intravascular lymphomatosis: A clinicopathologic study of 10 cases and assessment of response to chemotherapy
17. Association between the amount of mucin and p53 abnormalities in colorectal adenocarcinomas
18. Racial differences in the prognostic usefulness of MUC1 in colorectal adenocarcinomas
19. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma
20. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas
21. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer
22. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa
23. Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions
24. Molecular and histopathologic changes in the development of colorectal neoplasia
25. Initial management and follow-up surveillance of patients with colorectal adenomas
26. Follow-up after polypectomy: Consensus?
27. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup
28. Inactivation of both APC alleles in human and mouse tumors
29. Lessons from hereditary colorectal cancer
30. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients
31. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers
32. APC and p53 mutations in de novo colorectal adenocarcinomas
33. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis
34. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma
35. APC mutations are sufficient for the growth of early colorectal adenomas
36. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
37. Microsatellite instability in cancer of the proximal colon
38. Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic human gastrointestinal cancer
39. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers
40. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum
41. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients
42. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon
43. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons
44. Codon 201 Arg/Gly polymorphism of DCC (deleted in colorectal carcinoma) gene in flat- and polypoid-type colorectal tumors
45. Anti-malignin antibody in serum and other tumor marker determinations in breast cancer
46. Prognostic markers in rectal carcinoma
47. p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer
48. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27 (Kip1) in human colon cancer
49. Role of HER2 gene overexpression in breast carcinoma
50. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells
51. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
52. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
53. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
54. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct
55. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity
56. Targeting gene expression to tumor cells with loss of wild-type p53 function
57. P53 tumor suppressor gene therapy for cancer
58. Gene therapy for colon cancer
59. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
60. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
61. Proliferating cell nuclear antigen in rectal cancer: Predictor of response to preoperative irradiation
62. Rectal cancer: The influence of tumor proliferation on response to preoperative irradiation
63. Evaluation of biomarker modulation by Fenreinide in prostate cancer patients
64. Neuroendocrine tumors of the gastrointestinal tract
65. Lymphoid lesions of the gastrointestinal tract: A histologic, immunophenotypic, and genotypic analysis of 49 cases